| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -11,860 | -17,690 | -15,400 | -23,420 | -26,130 |
| Net Income Growth | +32.96% | -14.87% | +34.24% | +10.37% | -180.36% |
Tiziana Life Sciences Ltd (TLSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.
Fiscal Year End Date: 12/31